GH RESEARCH PLC (GHRS) Stock News

GH Research Announces Pricing of $150 Million Public Offering

GH Research Announces Pricing of $150 Million Public Offering

DUBLIN, Feb. 05, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives...

Unusual volume stocks in Tuesday's session

Let's have a look at the stocks with an unusual volume in today's session.

GH Research Announces Proposed Public Offering

GH Research Announces Proposed Public Offering

DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the...

Crude Oil Moves Higher; Owens & Minor Shares Plummet

Dow Falls 150 Points; ISM Manufacturing PMI Rises In January

GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day...

GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the...

GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents

GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents

Primary endpoint met in phase 2a POC trial in postpartum depression with a MADRS reduction from baseline of –35.4 points (p<0.0001, n=10) and 100% of...

GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates

GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024Phase 1 clinical...

3 Fast-Growing Stocks Analysts See Doubling in Price

Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches.

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and...

GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer

GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer

DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming...

3 Psychedelic Stocks to Ride to the Moon and Beyond

Psychedelic stocks are a hot, trending area of investment as the FDA continues to weigh regulatory considerations that will open the market.

Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns

Psychedelics could be a game-changer in treating mental health issues, creating substantial opportunities for top psychedelic stocks.